Peter Mulgrew
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 2
- Surgery 1
- Kawasaki Disease and Coronary Complications 1
- Journals
- The Lancet (5 papers)The Lancet Child & Adolescent Health (1 paper)Medical Entomology and Zoology (1 paper)
- Partner nations
- AustraliaUnited KingdomIndonesia
In The Last Decade
Peter Mulgrew
7 papers receiving 1.5k citations
Peter Mulgrew's Hit Papers
Peers
Comparison fields: 5 of 100
- Infectious Diseases 916
- Applied Microbiology and Biotechnology 49
- Neurology 319
- Internal Medicine 56
- Obstetrics and Gynecology 81
Countries citing papers authored by Peter Mulgrew
This map shows the geographic impact of Peter Mulgrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mulgrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mulgrew more than expected).
Fields of papers citing papers by Peter Mulgrew
This network shows the impact of papers produced by Peter Mulgrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mulgrew. The network helps show where Peter Mulgrew may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2024 | 23 | |
| 7 | No Place for Men | 1965 | 2 |
About Peter Mulgrew
Peter Mulgrew is a scholar working on Infectious Diseases, Surgery, Insect Science, Renewable Energy, Sustainability and the Environment and Obstetrics and Gynecology, having authored 7 papers that have together received 1.5k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (916 citations), Applied Microbiology and Biotechnology (49 citations), Neurology (319 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (81 citations). Peter Mulgrew has collaborated with scholars based in Australia, United Kingdom and Indonesia. Their work appears in journals such as The Lancet, The Lancet Child & Adolescent Health and Medical Entomology and Zoology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.